Jump to main content
eTG Complete
Index
Search
Home
Cardiovascular
Venous thromboembolism
Venous thromboembolism (VTE) treatment
Direct-acting oral anticoagulants for VTE treatment
Cardiovascular
Atherosclerotic cardiovascular disease risk estimation
Modifiable lifestyle risk factors for atherosclerotic cardiovascular disease
Lipid modification
Blood pressure reduction
Acute chest pain of possible cardiac origin
Acute coronary syndromes
Stable angina
Antithrombotic therapy after endovascular and cardiac interventions
Secondary prevention of atherosclerotic cardiovascular events
Peripheral artery disease
Pericarditis
Heart failure
Cardiac rehabilitation programs
Tachyarrhythmias
Bradyarrhythmias
Orthostatic hypotension
Pulmonary hypertension
Venous thromboembolism
Venous thromboembolism (VTE) prophylaxis
Venous thromboembolism (VTE) treatment
Overview of VTE
Approach to diagnosis of VTE
Approach to VTE treatment
Direct-acting oral anticoagulants for VTE treatment
Apixaban and rivaroxaban for VTE treatment
Dabigatran for VTE treatment
Warfarin for VTE treatment
Parenteral anticoagulants for VTE treatment
Duration of anticoagulant therapy for VTE
Extended therapy for VTE
Thrombolytic therapy and interventional procedures for VTE
VTE treatment during pregnancy and while breastfeeding
VTE treatment for patients with active cancer
Post-thrombotic syndrome of the lower limbs
Superficial vein thrombosis
References
Periprocedural management of patients with cardiovascular disease
Principles of anticoagulant therapy
Direct-acting oral anticoagulants for VTE treatment
Apixaban and rivaroxaban for VTE treatment
Dabigatran for VTE treatment
